Literature DB >> 30497881

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Sandeep R Das, Brendan M Everett, Kim K Birtcher, Jenifer M Brown, William T Cefalu, James L Januzzi, Rita Rastogi Kalyani, Mikhail Kosiborod, Melissa L Magwire, Pamela B Morris, Laurence S Sperling.   

Abstract

Entities:  

Keywords:  ASCVD; Expert Consensus Decision Pathway; GLP-1RA; SGLT2 inhibitor; T2D; cardiovascular risk reduction; diabetes

Mesh：

Year:  2018        PMID： 30497881     DOI： 10.1016/j.jacc.2018.09.020

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  79 in total

Review 1.  Cardiovascular Outcome Trials with Glucose-Lowering Drugs.

Authors:  Tina K Thethi; Anika Bilal; Richard E Pratley
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

Review 2.  Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering.

Authors:  Brendon L Neuen; David Z Cherney; Meg J Jardine; Vlado Perkovic
Journal:  CMAJ       Date:  2019-10-15       Impact factor: 8.262

Review 3.  Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes.

Authors:  Taichi Nagahisa; Yoshifumi Saisho
Journal:  Diabetes Ther       Date:  2019-08-22       Impact factor: 2.945

Review 4.  The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes.

Authors:  Mads Frederik Rasmussen
Journal:  Diabetol Int       Date:  2020-01-04

5.  Proteomics for personalized cardiovascular risk assessment: in pursuit of the Holy Grail.

Authors:  Peter Ganz; Rajat Deo; Ruth F Dubin
Journal:  Eur Heart J       Date:  2020-11-01       Impact factor: 29.983

Review 6.  Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.

Authors:  Javed Butler; Milton Packer; Stephen J Greene; Mona Fiuzat; Stefan D Anker; Kevin J Anstrom; Peter E Carson; Lauren B Cooper; Gregg C Fonarow; Adrian F Hernandez; James L Januzzi; Mariell Jessup; Rita R Kalyani; Sanjay Kaul; Mikhail Kosiborod; JoAnn Lindenfeld; Darren K McGuire; Marc S Sabatine; Scott D Solomon; John R Teerlink; Muthiah Vaduganathan; Clyde W Yancy; Norman Stockbridge; Christopher M O'Connor
Journal:  Circulation       Date:  2019-12-16       Impact factor: 29.690

Review 7.  Addressing Comorbidities in Heart Failure: Hypertension, Atrial Fibrillation, and Diabetes.

Authors:  Aakash Bavishi; Ravi B Patel
Journal:  Heart Fail Clin       Date:  2020-07-21       Impact factor: 3.179

8.  Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice.

Authors:  Thomas A Slater; Michael Drozd; Victoria Palin; Charlotte Bowles; Mohammed A Waduud; Rani Khatib; Ramzi A Ajjan; Stephen B Wheatcroft
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2020-07-01

9.  Cardiovascular and renal protection with sodium-glucose cotransporter type 2 inhibitors: new paradigm in type 2 diabetes management…and potentially beyond.

Authors:  André J Scheen
Journal:  Ann Transl Med       Date:  2019-07

Review 10.  Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.

Authors:  Jung-Im Shin
Journal:  Curr Diab Rep       Date:  2019-07-08       Impact factor: 4.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.